SUPERNUS PHARMACEUTICALS, INC.
SUPERNUS PHARMACEUTICALS, INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures on December 30, 2026. There are 6 upcoming events on record.
SUPERNUS PHARMACEUTICALS, INC. generates cash from operations, so a burn-based runway figure does not apply.
Across 53 concluded trials, 89% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| December 30, 2026 | BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures | Trial Milestone | Phase 1/Phase 2 |
| December 31, 2026 | Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder | Trial Milestone | Phase 2 |
| August 15, 2027 | RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures | Trial Milestone | Phase 2 |
| December 31, 2027 | Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy | Trial Milestone | Phase 2 |
| December 31, 2027 | SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures | Trial Milestone | Phase 2 |
| January 15, 2028 | Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD | Trial Milestone | Phase 4 |
Track SUPN alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open SUPN in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.